The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of outcomes with pembrolizumab monotherapy (P) versus combination with chemotherapy (P+C) in advanced non-small cell lung cancer (NSCLC).
 
Kartik Sehgal
No Relationships to Disclose
 
Ritu R. Gill
No Relationships to Disclose
 
Poorva Bindal
No Relationships to Disclose
 
Anita Geevarghese Koshy
No Relationships to Disclose
 
Danielle C McDonald
No Relationships to Disclose
 
Deepa Rangachari
Consulting or Advisory Role - Advance Medical; DynaMed
Research Funding - Abbvie/Stemcentrx; Bristol-Myers Squibb; Novocure
 
Daniel Botelho Costa
Honoraria - Pfizer; Takeda/Millennium
Consulting or Advisory Role - AstraZeneca; Takeda/Millennium
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Merck (Inst); Merrimack (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst); Takeda/Millennium (Inst)